Literature DB >> 116636

360 degrees prophylactic cryoretinopexy. A clinical and experimental study.

D M Robertson, I A Priluck.   

Abstract

Complications occurred after 360 degrees prophylactic cryoretinopexy in three of six eyes in which fellow eyes had previously developed aphakic retinal detachment. Two of the six prophylactically treated eyes developed retinal detachment in advance of anticipated cataract surgery, and a third developed vitreitis and progressive preretinal membrane formation after uncomplicated cataract extraction. In an experiment study with rhesus monkeys, preretinal membrane formation was produced by administering heavy freezes with 360 degrees cryoretinopexy. Although the quantities of cold were considered excessive for clinical use, the cryoretinopexy used clinically in this series must also be considered excessive. The use of 360 degrees cryoretinopexy in the management of eyes at high risk for retinal detachment must be considered judiciously. Particular caution must be exercised in administering cryoretinopexy to nondetached retinas so as to avoid heavy freezes, which destroy the linear retinal layers.

Entities:  

Mesh:

Year:  1979        PMID: 116636     DOI: 10.1001/archopht.1979.01020020448007

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


  4 in total

1.  Prophylactic circumferential cryopexy: a retrospective study of 106 eyes.

Authors:  J A Govan
Journal:  Br J Ophthalmol       Date:  1981-05       Impact factor: 4.638

2.  Diode laser photocoagulation for retinopathy of prematurity.

Authors:  T Tsitsis; W Tasman; J A McNamara; G Brown; J Vander
Journal:  Trans Am Ophthalmol Soc       Date:  1997

3.  Anterior chamber inflammation after transconjunctival cryosurgery.

Authors:  K Watanabe; H Ideta; J Nakatake; K Shinagawa; S Demizu; C Takenaka
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-02       Impact factor: 3.117

4.  [Peripheral retinal degenerations--treatment recommendations].

Authors:  A M Joussen; B Kirchhof
Journal:  Ophthalmologe       Date:  2004-10       Impact factor: 1.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.